Home › Companies › ADVERUM BIOTECHNOLOGIES INC. › 2023-2024
At ADVERUM BIOTECHNOLOGIES INC.'s shareholder meeting held June 17, 2024, in the 2023-2024 proxy season, 59 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 249 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED… — ADVERUM BIOTECHNOLOGIES INC.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ADVERUM BIOTECHNOLOGIES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ADVERUM BIOTECHNOLOGIES INC.’s Form 8-K, filed June 18, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 17, 2024: 6 items on ADVERUM BIOTECHNOLOGIES INC.’s Form 8-K, filed June 18, 2024: 3 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore ADVERUM BIOTECHNOLOGIES INC. in the interactive database Compare manager voting policies
These tallies are ADVERUM BIOTECHNOLOGIES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Soo Hong | 12,490,087 | -- | -- | 1,302,985 | 2,061,511 | 91% | Not verified | — |
| Elect Director: Dawn Svoronos | 11,414,932 | -- | -- | 2,378,140 | 2,061,511 | 83% | Not verified | — |
| Elect Director: Reed Tuckson, M.D. | 11,695,332 | -- | -- | 2,097,740 | 2,061,511 | 85% | Not verified | — |
| . Ratification of Selection of Independent Registered Public Accounting Firm Adverum's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of Adverum for its fiscal year ending December 31 | 15,816,318 | 32,193 | 6,072 | -- | -- | 99.7% | Approved | — |
| . Advisory Vote on Compensation of Named Executive Officers Adverum's stockholders approved, on an advisory basis, the compensation of Adverum's named executive officers as set forth in the Proxy Statement. The votes were | 12,184,261 | 1,589,765 | 19,046 | -- | 2,061,511 | 88% | Approved | — |
| . Approval of Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan Adverum's stockholders approved Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan. The votes were | 10,994,082 | 2,778,648 | 20,342 | -- | 2,061,511 | 80% | Approved | — |
Source: ADVERUM BIOTECHNOLOGIES INC., Form 8-K, filed with the SEC on June 18, 2024 — read the filing on EDGAR.
Each item below shows how the 59 asset managers that disclosed a ADVERUM BIOTECHNOLOGIES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Dawn Svoronos
ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Elect Director: Dawn Svoronos”): 11,414,932 for, 2,378,140 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 2,190,929 for, 125,046 withheld, 3,815 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,024,938 | 0 | 0 | 0 | For |
| Vanguard | 899,514 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 230,110 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 120,442 | Withhold |
| BlackRock | 25,627 | 0 | 0 | 0 | For |
| Charles Schwab | 10,713 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 3,247 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 0 | 1,656 | Withhold |
| American Century | 0 | 0 | 0 | 1,305 | Withhold |
| Nationwide | 0 | 0 | 0 | 1,073 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 570 | Withhold |
| Allianz | 0 | 0 | 396 | 0 | Abstain |
| John Hancock | 0 | 0 | 172 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 27 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Reed Tuckson, M.D.
ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Elect Director: Reed Tuckson, M.D.”): 11,695,332 for, 2,097,740 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 2,190,929 for, 125,046 withheld, 3,815 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,024,938 | 0 | 0 | 0 | For |
| Vanguard | 899,514 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 230,110 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 120,442 | Withhold |
| BlackRock | 25,627 | 0 | 0 | 0 | For |
| Charles Schwab | 10,713 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 3,247 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 0 | 1,656 | Withhold |
| American Century | 0 | 0 | 0 | 1,305 | Withhold |
| Nationwide | 0 | 0 | 0 | 1,073 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 570 | Withhold |
| Allianz | 0 | 0 | 396 | 0 | Abstain |
| John Hancock | 0 | 0 | 172 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 27 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Soo Hong
ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Elect Director: Soo Hong”): 12,490,087 for, 1,302,985 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 2,194,049 for, 122,098 withheld, 3,643 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,024,938 | 0 | 0 | 0 | For |
| Vanguard | 899,514 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 230,110 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 120,442 | Withhold |
| BlackRock | 25,627 | 0 | 0 | 0 | For |
| Charles Schwab | 10,713 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 3,247 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 0 | 1,656 | Withhold |
| American Century | 1,305 | 0 | 0 | 0 | For |
| Nationwide | 1,073 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 570 | 0 | 0 | 0 | For |
| Allianz | 0 | 0 | 396 | 0 | Abstain |
| John Hancock | 172 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 27 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
80% Approved · of votes cast
Description as filed by funds: TO APPROVE THE ADVERUM BIOTECHNOLOGIES, INC. 2024 EQUITY INCENTIVE AWARD PLAN.
ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Proposal 4: . Approval of Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan Adverum's stockholders approved Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan. The votes were as follows:”): 10,994,082 for, 2,778,648 against — passed, per its Form 8-K filed June 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval of Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan Adverum's stockholders approved Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan.”
Support: 80% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 1,468,061 for, 851,729 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 174,514 | 850,424 | 0 | 0 | Mixed |
| Vanguard | 899,514 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 230,110 | 0 | 0 | 0 | For |
| Dimensional | 120,442 | 0 | 0 | 0 | For |
| BlackRock | 25,627 | 0 | 0 | 0 | For |
| Charles Schwab | 10,713 | 0 | 0 | 0 | For |
| Jackson National | 3,247 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,656 | 0 | 0 | 0 | For |
| American Century | 0 | 1,305 | 0 | 0 | Against |
| Nationwide | 1,073 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 570 | 0 | 0 | 0 | For |
| Allianz | 396 | 0 | 0 | 0 | For |
| John Hancock | 172 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 27 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
88% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.
ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Proposal 3: . Advisory Vote on Compensation of Named Executive Officers Adverum's stockholders approved, on an advisory basis, the compensation of Adverum's named executive officers as set forth in the Proxy Statement. T”): 12,184,261 for, 1,589,765 against — passed, per its Form 8-K filed June 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Compensation of Named Executive Officers Adverum's stockholders approved, on an advisory basis, the compensation of Adverum's named executive officers as set forth in the Proxy Statement.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,024,938 | 0 | 0 | 0 | For |
| Vanguard | 899,514 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 230,110 | 0 | 0 | 0 | For |
| Dimensional | 120,442 | 0 | 0 | 0 | For |
| BlackRock | 25,627 | 0 | 0 | 0 | For |
| Charles Schwab | 10,713 | 0 | 0 | 0 | For |
| Jackson National | 3,247 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,656 | 0 | 0 | 0 | For |
| American Century | 1,305 | 0 | 0 | 0 | For |
| Nationwide | 1,073 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 570 | 0 | 0 | 0 | For |
| Allianz | 396 | 0 | 0 | 0 | For |
| John Hancock | 172 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 27 | 0 | 0 | 0 | For |
Fund voting reports, all 14 managers: 2,319,790 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 2,008,340 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 1,500,000 | 0 | 0 | 0 | For |
| Logos Global Management LP | 1,083,333 | 0 | 0 | 0 | For |
| Fidelity | 852,301 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 675,675 | 0 | 0 | 0 | For |
| 5AM Venture Management, LLC | 541,666 | 0 | 0 | 0 | For |
| Versant Venture Management, LLC | 472,531 | 0 | 0 | 0 | For |
| Laurion Capital Management LP | 438,919 | 0 | 0 | 0 | For |
| VR Adviser, LLC | 425,383 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 0 | 416,666 | 0 | 0 | Against |
| COMMODORE CAPITAL LP | 397,837 | 0 | 0 | 0 | For |
| BlackRock | 262,365 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 188,906 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 183,616 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 145,833 | 0 | 0 | 0 | For |
| PICTON MAHONEY ASSET MANAGEMENT | 119,154 | 0 | 0 | 0 | For |
| Renaissance | 98,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 85,719 | 0 | 0 | 0 | For |
| Point72 | 77,194 | 0 | 0 | 0 | For |
| Newtyn Management, LLC | 42,016 | 0 | 0 | 0 | For |
| Northern Trust | 40,793 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 25,165 | 0 | 0 | 0 | For |
| State Street | 24,349 | 0 | 0 | 0 | For |
| Dimensional | 19,695 | 0 | 0 | 0 | For |
| Charles Schwab | 10,713 | 0 | 0 | 0 | For |
Institutional-manager reports, all 51 managers: 9,758,183 for, 420,056 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD OF DIRECTORS, OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2024.
ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Proposal 2: . Ratification of Selection of Independent Registered Public Accounting Firm Adverum's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of Adverum ”): 15,816,318 for, 32,193 against — passed, per its Form 8-K filed June 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of Selection of Independent Registered Public Accounting Firm Adverum's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of Adverum for its fiscal year ending December 31, 2024.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 2,319,790 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,024,938 | 0 | 0 | 0 | For |
| Vanguard | 899,514 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 230,110 | 0 | 0 | 0 | For |
| Dimensional | 120,442 | 0 | 0 | 0 | For |
| BlackRock | 25,627 | 0 | 0 | 0 | For |
| Charles Schwab | 10,713 | 0 | 0 | 0 | For |
| Jackson National | 3,247 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,656 | 0 | 0 | 0 | For |
| American Century | 1,305 | 0 | 0 | 0 | For |
| Nationwide | 1,073 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 570 | 0 | 0 | 0 | For |
| Allianz | 396 | 0 | 0 | 0 | For |
| John Hancock | 172 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 27 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 20,890,733 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 4.91% |
| 2 | Vanguard | 4.31% |
| 3 | FRANKLIN STRATEGIC SERIES | 1.10% |
| 4 | Dimensional | 0.58% |
| 5 | BlackRock | 0.12% |
| 6 | Charles Schwab | 0.05% |
| 7 | Jackson National | 0.02% |
| 8 | Lincoln Financial | <0.01% |
| 9 | American Century | <0.01% |
| 10 | Nationwide | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | TCG Crossover Management, LLC | 9.61% |
| 2 | Vivo Capital, LLC | 7.18% |
| 3 | Logos Global Management LP | 5.19% |
| 4 | Fidelity | 4.08% |
| 5 | FRANKLIN ADVISERS INC | 3.23% |
| 6 | 5AM Venture Management, LLC | 2.59% |
| 7 | Versant Venture Management, LLC | 2.26% |
| 8 | Laurion Capital Management LP | 2.10% |
| 9 | VR Adviser, LLC | 2.04% |
| 10 | Avoro Capital Advisors LLC | 1.99% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | — | 13G |
| Leonard Braden Michael | — | 13D |
| BML Investment Partners, L.P. | — | 13G |
| TCG Crossover Fund II, L.P. | — | DEF14A |
| TCG Crossover GP II, LLC | — | 13G |
| Franklin Resources, Inc. | — | 13G |
| Entities affiliated with Franklin Advisers | — | DEF14A |
| Entities affiliated with Venrock Healthcare Capital Partners | — | DEF14A |
| Entities affiliated with Logos Global | — | DEF14A |
| FMR LLC | — | DEF14A |
Percentages above are of 20,890,733 shares outstanding, as reported by ADVERUM BIOTECHNOLOGIES INC. on its Form 10-Q dated May 6, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ADVERUM BIOTECHNOLOGIES INC.’s 10-Q dated May 6, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ADVERUM BIOTECHNOLOGIES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.
proxyvotesnow.com, “ADVERUM BIOTECHNOLOGIES INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/adverum-biotechnologies-inc/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.